Vivesto AB (VIVE.ST)
Stockholm · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 7.59 (+4.83%) as of
Key statistics
- Market cap
- 84.03M
- Forward P/E
- -75.90
- EPS (TTM)
- -4.12
- Dividend yield
- 0.00%
- 52-week range
- 6.50 – 23.76
- Beta
- 0.88
- Revenue (TTM)
- 8k
- Profit margin
- 0.00%
- Analyst target
- SEK 24.00
- Volume
- 5.07k
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Solna, Sweden
- Employees
- 4
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.